ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1976

Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019

Amar Suwal1, Biraj Shrestha2, Ibiyemi Oke2 and Anthony Donato2, 1Reading Hospital, Tower Health, Reading, PA, 2reading hospital- tower health, Reading, PA

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Mortality, Myocardial Infarction, population studies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions. There are conflicting results of previous studies about in-hospital outcomes of STEMI in patients with RA compared to patients without RA. This study aimed to compare in-hospital outcomes of the first episode of STEMI between patients with and without RA.

Methods: The NIS database represents a 20% stratified sample, or approximately 35 million U.S. hospital discharges annually. We conducted a retrospective study of hospitalizations with a primary diagnosis of STEMI and excluded patients with prior coronary artery disease (percutaneous coronary intervention [PCI], coronary artery bypass graft, or myocardial infarction) to capture only the first STEMI from 2016 to 2019. Our study population was then divided into two comparative cohorts, with RA, and without RA. We compared the two groups’ baseline demographics, comorbidities, and in-hospital outcomes. Continuous variables were expressed as mean, while categorical variables were represented in the percentage of the total population. Differences between groups were tested for continuous and categorical variables using t-test and Chi-square tests. Subsequently, we performed a multivariate logistic regression analysis for the same outcomes, adjusting for baseline factors significantly different (p< 0.1) in baseline characteristics by univariate analysis. Results of regression analyses were expressed as odds ratios (OR) with respective confidence intervals (CI) and p-values.

Results: Our analysis revealed that patients with RA were statistically more likely to be older, white, and female (Table 1). Interestingly, after adjusting for potential confounders with multivariable regression analysis, we found lower inpatient mortality in the first STEMI with RA cohort (adjusted OR: 0.74, 95% CI of 0.61-0.9, P value< 0.002) compared to the patients without RA (Table 2). However, there was no statistically significant difference between the two groups regarding complications, including repeat MI, acute heart failure, ventricular tachycardia, ventricular fibrillation, cardiac arrest, cardiogenic shock, and stroke during that hospitalization (Figure 1). Furthermore, there was no significant difference between groups in receiving invasive procedures, including coronary artery stenting (88.53 % vs. 90.14%, p-value 0.07) and coronary artery bypass (5.15% in RA vs. 5.65 % Non- RA patients, p-value: 0.45) (Table 1). Additionally, the annual mortality rate in patients with RA did not significantly change between 2016 and 2019 (average annual percentage change, –0.07%; P = 0.06). Also, we found no significant difference in the total length of stay between the two groups.

Conclusion: This nationwide study suggests that patients with RA with first STEMI have lower inpatient mortality than those without RA. However, further patient-level studies are needed to understand better the impact of newer biologics and the effect of risk factor modification on this patient subset.

Supporting image 1

Table 1. Baseline demographic characteristics, clinical comorbidities, and Invasive procedures for hospitalization for first STEMI in patients with and without Preexisting Rheumatoid Arthritis;
a: Comorbidities were coded using appropriate ICD_10 In the secondary diagnosis field as per supplemental material online

Supporting image 2

Supporting image 3

Figure 1: Unadjusted and adjusted odds ratios* for the overall complication, in-hospital mortality, acute heart failure, total stroke, repeat MI, Ventricular tachycardia, Ventricular fibrillation, cardiac arrest, cardiogenic shock
* Adjusted for age, race, female, heart failure, hypertension, COPD, peripheral vascular disease, valvular heart disease, cardiomyopathy, smoking


Disclosures: A. Suwal, None; B. Shrestha, None; I. Oke, None; A. Donato, None.

To cite this abstract in AMA style:

Suwal A, Shrestha B, Oke I, Donato A. Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019 [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/outcomes-of-the-first-episode-of-stemi-in-rheumatoid-arthritis-from-the-national-inpatient-sample-database-2016-2019/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-the-first-episode-of-stemi-in-rheumatoid-arthritis-from-the-national-inpatient-sample-database-2016-2019/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology